This project intends to design strategies that may ultimately contribute to long term control or even cure of HIV-1 infection. It will test hypotheses about mutational patterns of resistance to specific new drugs, drug susceptibility and replicative fitness phenotypes of drug-selected mutants, and the pathophysiology of failure of combination regimens and HIV's latent reservoir. It will also develop improved clinical monitoring for virus resistance and test a novel treatment strategy based on these hypotheses.
The specific aims of this project are: 1) To define the resistance genotypes and phenotypes selected in vivo during failure of combination regimens including either a PI, an NNRTI, or abacavir and to test cross-resistance of amprenavir- and abacavir-selected mutants. 2) To perform and develop in vitro characterizations of replicative fitness of mutant HIV-1s and the latent reservoir of HIV-1 relevant to the pathophysiology of virologic rebound during and after combination therapy. 3) To develop improved methods and strategies for clinical monitoring of antiretroviral resistance. 4. To perform a pilot, randomized clinical trial of proactive switching of antiretroviral combinations with or without intensive viral load monitoring versus the current standard strategy of changing drugs only after sustained virologic rebound is confirmed.
|Donahue, John P; Levinson, Rebecca T; Sheehan, Jonathan H et al. (2015) Genetic analysis of the localization of APOBEC3F to human immunodeficiency virus type 1 virion cores. J Virol 89:2415-24|
|Song, Chisu; Sutton, Lorraine; Johnson, Megan E et al. (2012) Signals in APOBEC3F N-terminal and C-terminal deaminase domains each contribute to encapsidation in HIV-1 virions and are both required for HIV-1 restriction. J Biol Chem 287:16965-74|
|Martin, Kenneth L; Johnson, Megan; D'Aquila, Richard T (2011) APOBEC3G complexes decrease human immunodeficiency virus type 1 production. J Virol 85:9314-26|
|Winham, Stacey J; Slater, Andrew J; Motsinger-Reif, Alison A (2010) A comparison of internal validation techniques for multifactor dimensionality reduction. BMC Bioinformatics 11:394|
|Vetter, Michael L; D'Aquila, Richard T (2009) Cytoplasmic APOBEC3G restricts incoming Vif-positive human immunodeficiency virus type 1 and increases two-long terminal repeat circle formation in activated T-helper-subtype cells. J Virol 83:8646-54|
|Vetter, Michael L; Johnson, Megan E; Antons, Amanda K et al. (2009) Differences in APOBEC3G expression in CD4+ T helper lymphocyte subtypes modulate HIV-1 infectivity. PLoS Pathog 5:e1000292|
|Charles, Macarthur; Noel, Francine; Leger, Paul et al. (2008) Survival, plasma HIV-1 RNA concentrations and drug resistance in HIV-1-infected Haitian adolescents and young adults on antiretrovirals. Bull World Health Organ 86:970-7|
|Donahue, John P; Vetter, Michael L; Mukhtar, Nizar A et al. (2008) The HIV-1 Vif PPLP motif is necessary for human APOBEC3G binding and degradation. Virology 377:49-53|
|Koelsch, Kersten K; Liu, Lin; Haubrich, Richard et al. (2008) Dynamics of total, linear nonintegrated, and integrated HIV-1 DNA in vivo and in vitro. J Infect Dis 197:411-9|
|Haas, David W; Geraghty, Daniel E; Andersen, Janet et al. (2006) Immunogenetics of CD4 lymphocyte count recovery during antiretroviral therapy: An AIDS Clinical Trials Group study. J Infect Dis 194:1098-107|
Showing the most recent 10 out of 44 publications